STERIS (STE) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" STE shares.
View STE analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 1 year price targets for STERIS's stock. Their STE share price forecasts range from $200.00 to $265.00. On average, they expect the company's stock price to reach $239.60 in the next year. This suggests a possible upside of 6.8% from the stock's current price.
View analysts price targets for STE or view top-rated stocks among Wall Street analysts.

STERIS's stock was trading at $184.69 at the start of the year. Since then, STE shares have increased by 21.5% and is now trading at $224.39.
View the best growth stocks for 2023 here.

STERIS saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 1,480,000 shares, a decline of 17.8% from the August 15th total of 1,800,000 shares. Based on an average daily trading volume, of 385,000 shares, the short-interest ratio is currently 3.8 days. Currently, 1.5% of the company's shares are short sold.
View STERIS's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our STE earnings forecast.

STERIS plc (NYSE:STE) released its quarterly earnings results on Tuesday, August, 1st. The medical equipment provider reported $2.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.14. The medical equipment provider had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.21 billion. STERIS had a net margin of 2.35% and a trailing twelve-month return on equity of 13.75%. STERIS's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.90 earnings per share.
Read the conference call transcript.

STERIS announced a quarterly dividend on Wednesday, July 26th. Stockholders of record on Wednesday, September 6th will be given a dividend of $0.52 per share on Friday, September 22nd. This represents a $2.08 annualized dividend and a yield of 0.93%. The ex-dividend date of this dividend is Tuesday, September 5th. This is a positive change from the stock's previous quarterly dividend of $0.47.
Read our dividend analysis for STE.

ETFs with the largest weight of STERIS (NYSE:STE) stock in their portfolio include Adaptive Core ETF (RULE), VictoryShares THB Mid Cap ESG ETF (MDCP), VanEck Environmental Services ETF (EVX), First Trust Indxx Medical Devices ETF (MDEV), iShares U.S. Medical Devices ETF (IHI), Nuveen ESG Mid-Cap Value ETF (NUMV), Running Oak Efficient Growth ETF (RUNN) and BlackRock Future Health ETF (BMED).

STERIS (NYSE:STE) pays an annual dividend of $2.08 per share and currently has a dividend yield of 0.92%. The company has been increasing its dividend for 18 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 170.49%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, STE will have a dividend payout ratio of 21.92% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for STE.

STERIS issued an update on its FY 2024 earnings guidance on Tuesday, August, 1st. The company provided earnings per share guidance of $8.60-$8.80 for the period, compared to the consensus estimate of $8.68. The company issued revenue guidance of $5.40 billion-$5.45 billion, compared to the consensus revenue estimate of $5.33 billion.

196 employees have rated STERIS Chief Executive Officer Walter M. Rosebrough, Jr. on Glassdoor.com. Walter M. Rosebrough, Jr. has an approval rating of 79% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other STERIS investors own include Johnson & Johnson (JNJ), Home Depot (HD), AT&T (T), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA) and Medtronic (MDT).

STERIS trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."

STERIS's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.91%), WCM Investment Management LLC (5.57%), State Street Corp (4.26%), Geode Capital Management LLC (2.12%), Alliancebernstein L.P. (1.53%) and Sustainable Growth Advisers LP (1.28%). Insiders that own company stock include Cary L Majors, Cary L Majors, Cynthia L Feldmann, David B Lewis, Jacqueline B Kosecoff, John Adam Zangerle, Julia Madsen, Karen L Burton, Michael J Tokich, Mohsen Sohi, Renato Tamaro and Walter M Rosebrough Jr.
View institutional ownership trends.

Shares of STE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STE stock can currently be purchased for approximately $224.39.

STERIS (NYSE:STE) has a market capitalization of $22.17 billion and generates $4.96 billion in revenue each year. The medical equipment provider earns $107.03 million in net income (profit) each year or $1.22 on an earnings per share basis.

The company employs 17,100 workers across the globe.

STERIS's mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The official website for the company is www.steris.com. The medical equipment provider can be reached via phone at (440) 354-2600, via email at julie_winter@steris.com, or via fax at 440-639-4457.